1 |
Moriyama, M. T., Ikeda, R., & Suzuki, K. (2003). Ryutan-shakan-to for the treatment of urination difficulty. Journal of Traditional Medicine, 20(5), 230-234.
|
2 |
Song, M. K., Park, S. H., Kang, J. S., Ahn, Y. M., Ahn, S. Y., Kim, Y. O., et al. (2010). Report of four cases of Paljung-san on lower urinary tract symptoms in patients with benign prostatic hyperplasia. Journal of Korean Oriental Medicine, 31(1), 153-161. https://www.koreascience.or.kr/article/JAKO201021147394355.pdf
|
3 |
Park, E., Lee, M. Y., Jeon, W. Y., Seo, C. S., You, S., & Shin, H. K. (2018). Paljung-San, a traditional herbal medicine, attenuates benign prostatic hyperplasia in vitro and in vivo. Journal of Ethnopharmacology, 218, 109-115. https://doi.org/10.1016/j.jep.2018.02.037
DOI
|
4 |
Tong, Y. & Zhou, R. Y. (2020). Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators of Inflammation, 2020:7958316. https://doi.org/10.1155/2020/7958316
DOI
|
5 |
Kim, J. J., Kim, H. J., An, B. K., Hong, W. S., Kim, W. H., Lee, S. I., et al. (1978). Studies on the therapeutics for liver diseases in herb remedies (VI): Experimental study on the effect on Ryongdamsakan-Tang. Kyung Hee University Oriental Medical Journal, 1, 31-5.
|
6 |
Brasure, M., MacDonald, R., Dahm, P., Olson, C. M., Nelson, V. A., Fink, H. A., et al. (2016). Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Review. Rockville (MD): Agency for Healthcare Research and Quality (US). http://www.ncbi.nlm.nih.gov/books/NBK368444/
|
7 |
Lee, S. W., Na, H. Y., Yoo, J. H., Ahn, Y. M., Ahn, S. Y., Kin, Y. O., et al. (2015). Effects of Paljeong-san on chronic nonbacterial prostatitis induced in rats by estradiol. Journal of Internal Korean Medicine, 36(2), 180-188. https://www.koreascience.or.kr/article/JAKO201525850332466.pdf
|
8 |
Elkelany, O. O., Owen, R. C., & Kim, E. D. (2015). Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. Therapeutics and Clinical Risk Management, 11, 507-513. https://doi.org/10.2147/TCRM.S80353
DOI
|
9 |
Yuan, H., Ma, Q., Ye, L., & Piao. G. (2016). The traditional medicine and modern medicine from natural products. Molecules, 21(5): 559. https://doi.org/10.3390/molecules21050559
DOI
|
10 |
Chen, J., Li, P., Sun, Z., Wang, C., Wang, T., & Wang, B. (2015). Five methods of syndrome differentiation and treatment for benign prostatic hyperplasia. Journal of Practical Traditional Chinese Internal Medicine, 29(11), 67-69. https://doi.org/10.13729/j.issn.1671-7813.2015.11.32
DOI
|
11 |
Seo, M. S., Jin, Y. S., & Jung, K. M. (1991). Effects of Yongdamsagantang and Yongdamsagantang -gamibang on the anti-allergic effect in rats and mice. Journal of Korean Oriental Pediatrics, 5, 15-27. https://www.koreascience.or.kr/article/JAKO199104637300724.pdf
|
12 |
Lee, T. Y. & Chang, H. H. (2010). Longdan Xiegan Tang has immunomodulatory effects on CD4+CD25+ T cells and attenuates pathological signs in MRL/lpr mice. International Journal of Molecular Medicine, 25(5), 677-85. https://doi.org/10.3892/ijmm_00000391
DOI
|
13 |
Furuya, S. & Takahashi, K. (2003). Clinincal investigation of the efficacy of Ryutan-shakan-to in the treatment of postoperative pain and discomfort following transurethral resection of the prostate. Kampo Medicine, 54(1), 183-189. https://www.jstage.jst.go.jp/article/kampomed1982/54/1/54_1_183/_pdf/-char/ja
DOI
|
14 |
Azimi, H., Khakshur, A. A., Aghdasi, I., Fallah-Tafti, M., & Abdollahi, M. (2012). A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflammation and Allergy Drug Targets, 11(3), 207-221. https://doi.org/10.2174/187152812800392715
DOI
|
15 |
Park, E., Lee, M. Y., Jeon, W. Y., Lee, N., Seo, C. S., & Shin, H. K. (2016). Inhibitory effect of Yongdamsagan-Tang water extract, a traditional herbal formula, on testosterone -induced benign prostatic hyperplasia in rats. Evidence Based Complement and Alternative Medicine, 2016, 1428923. https://doi.org/10.1155/2016/1428923
DOI
|
16 |
Park, E., Lee, M. Y., Seo, C. S., Jeon, W. Y., & Shin, H. K. (2017). Yongdamsagan-tang, a traditional herbal formula, inhibits cell growth through the suppression of proliferation and inflammation in benign prostatic hyperplasia epithelial-1 cells. Journal of Ethnopharmacology, 209, 230-235. https://doi.org/10.1016/j.jep.2017.08.002
DOI
|
17 |
Ma, C. H., Lin, W. L., Lui, S. L., Cai, X. Y., Wong, V. T., Ziea, E., et al. (2013). Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systemic review of randomized controlled trials. Asian Journal of Andrology, 15(4), 471-482. https://doi.org/10.1038/aja.2012.173
DOI
|
18 |
Kruslin, B., Tomas, D., Dzombeta, T., Milkovic-Perisa, M., & Ulamec, M. (2017). Inflammation in prostatic hyperplasia and carcinoma-basic scientific approach. Frontiers in Oncology, 7, 77. https://doi.org/10.3389/fonc.2017.00077
DOI
|
19 |
Agbabiaka, T. B., Wider, B., Watson, L. K., & Goodman, C. (2017). Concurrent use of prescription drugs and herbal medicinal products in older adults: A systematic review. Drugs Aging, 34, 891-905. https://doi.org/10.1007/s40266-017-0501-7
DOI
|
20 |
Amitani, M., Amitani, H., Sloan, R. A., Suzuki, H., Sameshima, N., Asakawa, A., et al. (2015). The translational aspect of complementary and alternative medicine for cancer with particular emphasis on Kampo. Frontiers in Pharmacology, 6, 150. https://doi.org/10.3389/fphar.2015.00150
DOI
|
21 |
Huang, S. M. & Lesko, L.J. (2004). Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? Journal of Clinical Pharmacology, 44(6), 559-569. https://doi.org/10.1177/0091270004265367
DOI
|
22 |
Kim, E. H., Larson, J. A., & Andriole, G. L. (2016). Management of Benign Prostatic Hyperplasia. Annual Review of Medicine, 67, 137-151. https://doi.org/10.1146/annurev-med-063014-123902
DOI
|
23 |
Lim, J. H., Lee, J. R., Kim, S. C., & Jee, S. Y. (2007). Inhibitory effect of Yongdamsagantang water extract in IL-6 and nitric oxide production in lipopolysaccharide-activated RAW264.7 cells. Oriental Pharmacy and Experimental Medicine, 7(3), 321-329. https://doi.org/10.3742/OPEM.2007.7.3.321
DOI
|
24 |
Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T.C., et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metabolism and Disposition, 32(11), 1201-1208. https://doi.org/10.1124/dmd.104.000794
DOI
|
25 |
Kramer, G., Mitteregger, D., & Marberger, M. (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European Urology, 51(5), 1202-1216. https://doi.org/10.1016/j.eururo.2006.12.011
DOI
|
26 |
Vuichoud, C. & Loughlin, K. R. (2015). Benign prostatic hyperplasia: epidemiology, economics and evaluation. The Canadian Journal of Urology, 22(Suppl 1), 1-6. https://www.canjurol.com/html/free-articles/JUV22I5S1F_06_DrLoughlin.pdf
|
27 |
Olesovsky, C. & Kapoor, A. (2016). Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Therapeutic Advances in Urology, 8(4), 257-271. https://doi.org/10.1177/1756287216650132
DOI
|
28 |
Di Silverio, F., Bosman, C., Salvatori, M., Albanesi, L., Proietti Pannunzi, L., Ciccariello, M., et al. (2005). Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). European Urology, 47(1), 72-79. https://doi.org/10.1016/j.eururo.2004.08.024
DOI
|
29 |
Grimstein, M. & Huang, S.M. (2018). A regulatory science viewpoint on botanical-drug interactions. Journal of Food and Drug Analysis, 26(2S), S12-S25. https://doi.org/10.1016/j.jfda.2018.01.013
DOI
|
30 |
Prueksaritanont, T., Chu, X., Gibson, C., Cui, D., Yee, K. L., Ballard, J., et al. (2013). Drug-drug interaction studies: regulatory guidance and an industry perspective. The AAPS Journal, 15(3), 629-645. https://doi.org/10.1208/s12248-013-9470-x
DOI
|
31 |
Hulin-Curtis, S. L., Petit, D., Figg, W. D., Hsing, A. W., & Reichardt, J. K. (2010). Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncology, 6(12), 1897-1913. https://doi.org/10.2217/fon.10.149
DOI
|